ZIM Laboratories Limited (NSE:ZIMLAB)

Market Cap	6.56B +13.2%
Revenue (ttm)	3.74B -1.2%
Net Income	58.38M -52.0%
EPS	1.19 -52.3%
Shares Out	n/a
PE Ratio	112.36
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,463
Open	118.58
Previous Close	118.58
Day's Range	116.21 - 118.58
52-Week Range	59.31 - 133.90
Beta	0.83
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 11, 2026

About ZIM Laboratories

ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, directly compressible granules, tablets, capsules, dry syrup, and oral thin films. The company offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1984
• Employees: 632
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ZIMLAB

Financial Performance

In fiscal year 2026, ZIM Laboratories's revenue was 3.74 billion, a decrease of -1.22% compared to the previous year's 3.79 billion. Earnings were 58.38 million, a decrease of -52.01%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 22, 2026

Data Sources Report a data error